These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

96 related articles for article (PubMed ID: 3319861)

  • 1. Unchanged insulin secretion and glucose tolerance but increased insulin clearance during long-term calcium antagonism with felodipine in essential hypertension.
    Katzman PL; Hulthén UL; Hökfelt B
    Horm Metab Res; 1987 Sep; 19(9):426-9. PubMed ID: 3319861
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Glucoregulatory hormone response to insulin-induced hypoglycaemia following long-term calcium antagonism with felodipine in patients with essential hypertension.
    Katzman PL; Hulthén UL; Hökfelt B
    Acta Endocrinol (Copenh); 1987 Dec; 116(4):473-8. PubMed ID: 3321819
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Glucose tolerance and secretion and clearance of insulin during long term felodipine treatment.
    Katzman PL; Hulthén UL; Hökfelt B
    Drugs; 1987; 34 Suppl 3():93-4. PubMed ID: 3327685
    [No Abstract]   [Full Text] [Related]  

  • 4. Calcium antagonism with felodipine in essential hypertension. Effects on cardiovascular and renal function, the sympathetic and the renin-angiotensin-aldosterone systems, glucose tolerance and glucoregulatory hormones.
    Katzman PL
    Acta Med Scand Suppl; 1987; 720():1-62. PubMed ID: 3328471
    [No Abstract]   [Full Text] [Related]  

  • 5. Glucose tolerance in hypertensive patients during treatment with the calcium antagonist, felodipine.
    Hedner T; Elmfeldt D; Von Schenck H; Sjögren E; Smith U
    Br J Clin Pharmacol; 1987 Aug; 24(2):145-9. PubMed ID: 3304386
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Catecholamines, renin-angiotensin-aldosterone, and cardiovascular response during exercise following acute and long-term calcium antagonism with felodipine in essential hypertension.
    Katzman PL; Hulthén UL; Hökfelt B
    J Cardiovasc Pharmacol; 1987 Oct; 10(4):439-44. PubMed ID: 2444797
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effects of nifedipine and nitrendipine on insulin secretion in obese patients.
    Valensi P; Uzzan B; Attali JR; Perret G
    J Cardiovasc Pharmacol; 1991; 18 Suppl 1():S91-3. PubMed ID: 1723467
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Nitrendipine and metabolic balance.
    Ferrara LA; Marotta T
    J Cardiovasc Pharmacol; 1991; 18 Suppl 5():S19-21. PubMed ID: 1725797
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Felodipine in the treatment of hypertensive type II diabetics: effect on glucose homeostasis.
    Kjellström T; Blychert E; Lindgärde F
    J Intern Med; 1991 Mar; 229(3):233-9. PubMed ID: 2007841
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Renal effects of acute and long-term treatment with felodipine in essential hypertension.
    Hulthén UL; Katzman PL
    J Hypertens; 1988 Mar; 6(3):231-7. PubMed ID: 3361121
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Insulin sensitivity and beta-cell function in essential hypertension and normotensive first-degree relatives of hypertensive subjects.
    Cabezas-Cerrato J; Garcia-Estevez DA; Araújo-Vilar D
    Diabetes Metab; 1997 Nov; 23(5):402-8. PubMed ID: 9416432
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Felodipine in arterial hypertension. Double-blind comparison with atenolol].
    Andrejak M; Witchitz S; Morand P; Lesbre JP; Raveau-Landon C
    Therapie; 1989; 44(3):167-70. PubMed ID: 2675377
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Felodipine therapy may not alter glucose and lipid metabolism in hypertensives. Felodipine Multicenter Prospective Study Group in Japan.
    Shionoiri H; Takizawa T; Ohyama Y; Ishii J; Katayama S; Nagasawa T; Kitamoto K; Nagasawa K; Hariya Y; Sato R
    Hypertension; 1994 Jan; 23(1 Suppl):I215-9. PubMed ID: 8282362
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Felodipine, a new calcium antagonist, as monotherapy in mild or moderate hypertension. Cooperative study group.
    Drugs; 1987; 34 Suppl 3():139-48. PubMed ID: 2894973
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Does long-term blood pressure reduction in patients with essential hypertension improve concomitant metabolic disorders?].
    Hauner H; Meissner C
    Med Klin (Munich); 1994 Aug; 89(8):403-9. PubMed ID: 7968872
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Enhancement of exogenous triglyceride removal following calcium channel blockade.
    Marotta T; Ferrara LA; Pasanisi F; Rubba P; Iovine C; Mancini M
    Artery; 1989; 16(6):312-26. PubMed ID: 2679494
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Cardiovascular-risk reduction: initial diuretic therapy compared with calcium-antagonist (felodipine) therapy for primary hypertension.
    Sudhir K; Jennings GL; Bruce A
    Med J Aust; 1989 Sep; 151(5):277-9. PubMed ID: 2671617
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effects of a new diuretic piretanide on glucose tolerance, insulin secretion and 125I-insulin binding.
    Harno K; Välimäki M; Verho M
    Eur J Clin Pharmacol; 1985; 27(6):697-700. PubMed ID: 3886396
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Antihypertensive drugs and glucose metabolism: a comparison between a diuretic and felodipine, a new calcium antagonist, when added to a beta-blocker in non-diabetic hypertensive women.
    Bengtsson C; Lapidus L
    Scott Med J; 1994 Jun; 39(3):71-3. PubMed ID: 8720766
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Effect of the calcium antagonist nicardipine hydrochloride on glucose tolerance and insulin secretion.
    Kihara A
    Am Heart J; 1991 Jul; 122(1 Pt 2):363-9. PubMed ID: 2053557
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.